Bausch & Lomb v. Lupin: Vasoconstriction Patent Case Dismissed in 97 Days
Bausch & Lomb, Inc., Bausch & Lomb Ireland Limited, and Eye Therapies, LLC filed a patent infringement action against Lupin Limited and three affiliated entities in the District of New Jersey, asserting US11596600B2 covering vasoconstriction compositions and methods of use. The case was dismissed after just 97 days, following a stipulation and order entered by Magistrate Judge Rukhsanah L. Singh.
Pharma patent dispute ends swiftly via stipulated dismissal
On May 3, 2023, Bausch & Lomb, Inc., together with co-plaintiffs Bausch & Lomb Ireland Limited and Eye Therapies, LLC, filed an infringement action in the U.S. District Court for the District of New Jersey against Lupin Limited, Lupin Atlantis Holdings S.A., Lupin Pharmaceuticals, Inc., and Lupin, Inc. The asserted patent, US11596600B2, covers vasoconstriction compositions and methods of use — a formulation area directly relevant to ophthalmic products.
The recorded basis of termination is 'Case Dismissed.' The docket order states that civil case termination followed Docket Entry 17, described as a 'Stipulation and Order regarding schedule between Plaintiffs and Defendants,' signed by Magistrate Judge Rukhsanah L. Singh on July 6, 2023, with the case formally closed on August 8, 2023. The specific terms underlying the stipulation are not disclosed in the available record.
The 97-day resolution is notably swift for pharmaceutical patent litigation of this type, where cases routinely extend for years. What drove the early resolution — whether related to ANDA status, licensing discussions, or other commercial considerations — is not apparent from the public record. The absence of any merits ruling means the validity and enforceability of US11596600B2 remain unaddressed by this court.
See Complete Case & Patent Analysis →Filing to Case Dismissed in 97 days
97 days from filing to dismissal — well below the median ANDA/pharma patent case duration
US11596600B2 — Vasoconstriction Compositions and Methods of Use
Any pharmaceutical or ophthalmic product developer working with vasoconstriction compositions — whether for prescription or OTC ocular use — should assess freedom-to-operate against US11596600B2. The patent emerged from this litigation without any adverse ruling on its validity or claim scope, and the involvement of both an operating company (Bausch & Lomb) and a specialised licensing entity (Eye Therapies, LLC) suggests active enforcement intent.
Official order — verbatim text
The docket records termination via a Stipulation and Order regarding scheduling, signed by Magistrate Judge Singh on July 6, 2023, with formal closure entered August 8, 2023. The order's framing as a scheduling stipulation that triggered case termination is noted; the specific terms agreed between the parties are not disclosed in the available record, and no findings on infringement or validity were made.
Case dismissed: what the stipulated termination means for both parties
Dismissal via stipulation: no merits ruling issued
The case was terminated pursuant to a Stipulation and Order entered by Magistrate Judge Singh. A stipulated dismissal is a procedural resolution agreed to by both parties and endorsed by the court. No infringement finding, validity ruling, or damages determination was made. The specific terms of the parties' agreement are not disclosed in the available public record.
No merits adjudicationUS11596600B2 validity left intact but untested
Because no court ruled on the merits, US11596600B2 emerges from this litigation with its validity and enforceability neither confirmed nor challenged by judicial decision. Bausch & Lomb and Eye Therapies retain the patent and its presumption of validity. Whether any agreement between the parties affects future enforcement is not disclosed in the public record.
Patent validity untestedLupin entities face no adverse judgment from this action
The Lupin entities — Lupin Limited, Lupin Atlantis Holdings S.A., Lupin Pharmaceuticals, Inc., and Lupin, Inc. — exit this litigation without an adverse infringement or validity finding. What obligations, if any, they assumed under the stipulation are not reflected in the public record. Their ability to commercialise relevant vasoconstriction products going forward depends on factors not determinable from this docket alone.
No adverse findingSwift exit leaves sector questions open on vasoconstriction IP
The rapid dismissal without merits adjudication is consistent with early-stage negotiated resolution in pharmaceutical patent disputes, though no settlement terms are confirmed. For other ophthalmic or generic pharma companies operating in the vasoconstriction formulation space, US11596600B2 remains a live, presumptively valid patent with no judicial ruling narrowing or limiting its claims.
Patent remains enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bausch & Lomb, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Bausch & Lomb Ireland Limited | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Eye Therapies, LLC | Company | Search in Eureka ↗ |
| Defendant | Lupin Limited | Individual | /Search in Eureka ↗ |
| Co-Defendant | Lupin Atlantis Holdings, S.A. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni | Attorney | Counsel for Bausch & Lomb, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Bausch & Lomb, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Lupin LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the ophthalmic vasoconstriction patent space
Forward-looking patent and R&D intelligence derived from this Bausch & Lomb v. Lupin dispute and the vasoconstriction formulation technology at its centre.
Bausch & Lomb and Eye Therapies: ophthalmic formulation filing activity
Bausch & Lomb's co-assertion with Eye Therapies, LLC suggests a structured IP portfolio around ophthalmic vasoconstriction formulations. Mapping their combined filing activity in this domain can reveal prosecution strategy, continuation chains from US11596600B2, and adjacent claim coverage that may affect product development decisions for any company in the ocular pharmaceutical space.
Portfolio mappingFiling trends in ophthalmic vasoconstriction and redness-relief formulations
The vasoconstriction ophthalmic space — covering ingredients, delivery systems, and preservative-free formulations — has attracted growing patent activity as the OTC redness-relief market evolves post-tetryzoline. Tracking filing trends in this domain helps R&D teams identify crowded claim areas, whitespace, and emerging formulation approaches that could support differentiated product development.
Filing trend analysisLupin's patent activity in ophthalmic and specialty pharmaceutical formulations
Lupin Limited and its affiliates maintain an active pharmaceutical patent portfolio spanning generics and specialty formulations. Analysing Lupin's own filings in the ophthalmic segment — including any defensive applications or continuations in the vasoconstriction space — can reveal their R&D direction and potential counter-positioning against branded formulation patents.
Competitor positioningAdjacent innovation opportunities near vasoconstriction composition claims
US11596600B2 covers specific vasoconstriction compositions and methods of use. Identifying claim boundaries and examining adjacent formulation approaches — including alternative active agents, novel delivery mechanisms, or preservative-free variants — may reveal whitespace for R&D investment that avoids the asserted patent's coverage while addressing the same clinical need.
Whitespace identificationSimilar ophthalmic patent infringement cases in U.S. District Courts
Explore related pharmaceutical patent infringement actions involving ophthalmic formulations and vasoconstriction compositions filed in U.S. District Courts.
What this case signals for the ophthalmic pharma IP landscape
A 97-day dismissal in an ophthalmic patent dispute raises strategic questions for any company active in the vasoconstriction formulation space.
US11596600B2 remains untested: enforce or design-around risk persists
No court has ruled on the validity or scope of US11596600B2. For generic manufacturers and ophthalmic product developers, this means the patent retains full presumptive validity and cannot be dismissed as commercially moot. Any company working in vasoconstriction formulations should treat this patent as an active enforcement risk until it faces a substantive legal challenge.
Multi-entity Lupin structure signals coordinated ANDA defence posture
The involvement of four Lupin entities — spanning the parent, a Swiss holding company, a U.S. pharma subsidiary, and a U.S. operating entity — suggests a coordinated global response to pharmaceutical patent enforcement. This structure is commonly associated with ANDA-related litigation. Competitors and litigation monitors should track Lupin's regulatory filings in the vasoconstriction product category for further activity.
Bausch v Lupin — key questions answered
The case was dismissed. The recorded basis of termination is 'Case Dismissed.' The docket reflects that civil case termination was entered on August 8, 2023, following a Stipulation and Order regarding schedule entered by Magistrate Judge Rukhsanah L. Singh on July 6, 2023. No merits ruling on infringement or validity was issued. The specific terms are not disclosed in the available record.
The plaintiffs asserted US11596600B2 (application number US17/585395), covering vasoconstriction compositions and methods of use. This is an ophthalmic formulation patent relevant to ocular redness-relief and vasoconstriction product categories. No claim construction or validity determination was made in this litigation.
The case was dismissed 97 days after filing, which is notably rapid for pharmaceutical patent litigation. The dismissal followed a Stipulation and Order entered by Magistrate Judge Singh. What drove the swift resolution — whether commercial negotiations, ANDA-related considerations, or other factors — is not apparent from the public record. No explanation is provided in the available docket entries.
The plaintiffs were Bausch & Lomb, Inc., Bausch & Lomb Ireland Limited, and Eye Therapies, LLC. The defendants were Lupin Limited, Lupin Atlantis Holdings S.A., Lupin Pharmaceuticals, Inc., and Lupin, Inc. The case was filed in the U.S. District Court for the District of New Jersey on May 3, 2023.
No. Because the case was dismissed without any merits adjudication, US11596600B2 retains its full presumption of validity. No court issued a ruling on the patent's claims, scope, or enforceability in this action. The patent remains a live enforcement risk for companies operating in the vasoconstriction ophthalmic formulation space.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.